Processa Pharmaceuticals, Inc. · NASDAQ:PCSA
Processa Pharmaceuticals — Investor Presentation (November 2026)
21 slides from Processa Pharmaceuticals's investor presentation, November 2026
Slide 1: Company Overview
Company Overview November 2026 Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.
Slide 2: Disclaimers
Disclaimers The information in this Presentation has been prepared by Processa Pharmaceuticals, Inc. ("Processa"), including its subsidiary Vidya Therapeutics, Inc. ("Vidya" and, together with Processa and each of Processa's subsidiaries, the "company") and contains information pertaining to the bus
Slide 3: Processa acquired Vidya in a sign-and-close reverse merger
Processa acquired Vidya in a sign-and-close reverse merger, establishing a foundation for current I&I strategy, anchored by VT-7208 OVERVIEW • Definitive merger agreement for a stock-for-stock transaction • Vidya’s outstanding equity interests exchanged for a combination of shares of Processa common
Slide 4: Our strategy: advancing differentiated therapeutic programs for immunological and inflammatory disease
Our strategy: advancing differentiated therapeutic programs for immunological and inflammatory disease POTENTIAL PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 INDICATIONS Food allergy VT-7208 Chronic spontaneous (BTK inhibitor) urticaria Relapsing multiple sclerosis IgG-driven Oral FcRn autoimmune dis
Slide 5: VT-7208: A potentially best-in-class, oral, once-daily BTK inhibitor
VT-7208 A potentially best-in-class, oral, once-daily BTK inhibitor
Slide 6: VT-7208 expected to provide multiple value creation paths
VT-7208 expected to provide multiple value creation paths CLINICALLY VALIDATED INDICATION EXPANSION CLEAR UNMET NEED / MECHANISM POTENTIAL LARGE ADDRESSABLE MARKETS • BTK inhibition established across Parallel development in CSU, food CSU: >1.7M U.S. patients1 autoimmune diseases allergy and relapsi
Slide 7: BTK is a compelling target
BTK is a compelling target BTK offers the potential to modulate both adaptive and innate immune pathways CENTRAL IMMUNE B-CELLS (ADAPTIVE) MYELOID CELLS (INNATE) SIGNALING NODE BCR FcRn BCR signaling drives BTK’s dual role FcRn signaling drives • Proliferation • Links adaptive and innate • Myeloid c
Slide 8: Strong and differentiated preclinical profile supports advancement into the clinic
Strong and differentiated preclinical profile supports advancement into the clinic Strong CNS • Potent in vitro and in vivo with strong Penetration peripheral and CNS target engagement • Consistent efficacy observed across disease models • Clean metabolic profile with predictable PK VT7208 • Low liv
Slide 9: VT-7208 Phase 1 study design enables efficient dose escalation and translational readouts
VT-7208 Phase 1 study design enables efficient dose escalation and translational readouts; currently advancing into Phase 2 PoC SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE 60 mg 10 mg QD x 7d SAFETY SRC >95% BTK TO ≥24 hrs SRC 20 mg 20 mg QD x 7d Food Effect 5 mg Cohort 20 mg 6 VT-7208:2 PBO per c
Slide 10: VT-7208's Phase 1 study results demonstrated favorable safety and tolerability profile
VT-7208’s Phase 1 study results demonstrated favorable safety profile and tolerability profile PARAMETER SAD FOOD COHORT MAD (QDX7) 5 mg 20 mg 60 mg 20 mg 10 mg 20 mg SAEs 0/6 0/6 0/6 0/8 0/6 0/6 Grade 3 or higher 0/6 0/6 0/6 0/8 0/6 0/8 1/6 1/8 Related AEs 0/6 0/6 0/6 0/6 Headache (G1) Headache (G1
Slide 11: VT-7208's predictable PK supports low, once-daily oral dosing
VT-7208’s predictable PK supports low, once-daily oral dosing SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE ● 5 mg ● 10 mg ● 20 mg ● 60 mg ● 10 mg ● 20 mg ━ SS ╍ CSF 1,000 1,000 100 VT-7208 Conc (ng/mL) VT-7208 Conc (ng/mL) 100 10 10 1 CSF 1 IC₅₀, human iPSC-derived microglia 0.1 0.1 0.01 0 12 24 36
Slide 12: VT-7208 demonstrated robust and sustained BTK target occupancy at ≥5 mg/day
VT-7208 demonstrated robust and sustained BTK target occupancy at ≥ 5 mg/day SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE ▲ Placebo ▲ 5 mg ▲ 20 mg ▲ 60 mg ▼ Placebo ▼ 10 mg ▼ 20 mg 100 100 Peripheral Target Occupancy (%) Peripheral Target Occupancy (%) 95% 95% 80 75 60 40 50 20 25 0 -20 0 0 12 24 3
Slide 13: Robust and sustained inhibition of pBTK demonstrated modulation of signaling pathway
Robust and sustained inhibition of pBTK demonstrated modulation of signaling pathway MULTIPLE ASCENDING DOSE ■ Placebo ■ 10 mg □ 20 mg 100 75 pBTK Inhibition (%) 50 25 0 -25 -50 0 48 96 144 192 240 288 336 Time (hrs) • Sustained inhibition of pBTK demonstrates the potential for durable pharmacodynam
Slide 14: VT-7208 Phase 1 complete; now advancing into Phase 2 PoC studies
VT-7208 Phase 1 complete; now advancing into Phase 2 PoC studies in Food Allergy, CSU, & Relapsing MS with data expected in 2027 and 2028 TARGET / ASSET PRECLINICAL TRANSLATIONAL CLINICAL STRATEGIC ü Validated biology ü Low risk of ü Predictable PK ü Well-defined PoC ü Capital-efficient hepatotoxici
Slide 15: Oral FcRn antagonist
Oral FcRn antagonist Potentially best-in-class, preclinical oral neonatal Fc receptor (FcRn) antagonist
Slide 16: Oral FcRn antagonist program complements VT-7208 against a clinically validated immune target
Oral FcRn antagonist program complements VT-7208 against a clinically validated immune target ANNOUNCED OCTOBER 2026 1 2 3 4 Partnership Modality Differentiation Program progression Research collaboration Macrocyclic peptide against Potential oral alternative Lead optimization through and exclusive
Slide 17: Blocking FcRn clears the pathogenic IgG that drives autoimmune disease
Blocking FcRn clears the pathogenic IgG that drives autoimmune disease FcRn binds IgG inside cells and recycles it back to the blood, sparing it from lysosomal degradation. This gives IgG its long half-life of ~3 weeks. Blocking FcRn sends IgG, including disease-causing autoantibodies, to the lysoso
Slide 18: FcRn is a commercially validated, rapidly growing therapeutic class
FcRn is a commercially validated, rapidly growing therapeutic class $4.15B Approved FcRn Therapies $4.15B $2.2B VYVGART argenx RYSTIGGO UCB IMAAVY JnJ VYVGART 2025 global net sales A validated pathway with established prescriber infrastructure +90% vs. 2024 2024 2025 and proven commercial demand Str
Slide 19: No oral FcRn therapeutic is currently in clinical development
No oral FcRn therapeutic is currently in clinical development PROGRAM MODALITY STAGE Generian / Vidya Macrocycle Preclinical Argenx + Unnatural Products Macrocycle Preclinical Peptide Preclinical Covant Small molecule Early discovery Curie Small molecule Preclinical Fudan Small molecule Early discov
Slide 20: Expected capitalization post Series A conversion
Expected capitalization post Series A conversion Expected capitalization Approximate shares Common shares outstanding (Nov 9, 2026) 2.8 million Series A preferred, as-converted* 306.6 million Total 309.4 million * Subject to stockholder approval and applicable beneficial ownership limitations. Exclu
Slide 21: Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.
Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.
Processa Pharmaceuticals — Investor Presentation (November 2026) on 6ix